[Oxalate stone prophylaxis by alkalinizing therapy (author's transl)]

Area of Science:

• Nephrology
• Urology
• Biochemistry

Background:

• Hypocitraturia is prevalent in oxalate stone formers, often co-occurring with hypercalciuria.
• Oxalate stones represent a significant clinical challenge in urology and nephrology.

Purpose of the Study:

• To evaluate the efficacy of short-term and long-term alkalinizing therapy using sodium-potassium-citrate in patients with oxalate stones.
• To assess the impact of this therapy on urinary citrate and calcium excretion and stone recurrence.

Main Methods:

• Administered short-term (3 weeks) and long-term (10-20 months) alkalinizing therapy with sodium-potassium-citrate (Uralyt-U) to patients with oxalate stones.
• Monitored 24-hour urinary excretion of citrate, calcium, oxalate, urate, magnesium, and phosphate.
• Tracked stone recurrence in patients undergoing long-term therapy.

Main Results:

• Short-term therapy led to a 118% increase in citrate and a 29.5% decrease in calcium excretion.
• Urinary oxalate, urate, magnesium, and phosphate levels remained unchanged.
• Long-term therapy maintained these effects, with no stone recurrence observed in seven patients after at least one year of treatment.

Conclusions:

• Sodium-potassium-citrate is an effective treatment for hypocitraturia and hypercalciuria in oxalate stone formers.
• Alkalinizing therapy demonstrates potential for preventing recurrent oxalate stone formation.